PMID: 20135568Feb 6, 2010Paper

Antithyroid peroxidase antibodies in patients with high normal range thyroid stimulating hormone

Family Medicine
Ana Sofia ZelayaCarlos A Moreno

Abstract

Hypothyroidism is linked to heart disease and decreased quality of life. Since screening guidelines for the general population are controversial, and physicians use clinical judgment in deciding to order thyroid stimulating hormone (TSH), high-normal levels of TSH pose a dilemma. This study's objective was to compare rates of positive anti-thyroid peroxidase antibodies (antiTPO) tests in persons with high-normal versus low-normal TSH levels. Physicians at a publicly funded family medicine outpatient clinic used a standard clinical set of criteria to identify patients in need of TSH testing. Patients with non-thyroid diseases or conditions that affect TSH were excluded. A total of 143 patients over 18 years of age presented with symptoms necessitating TSH testing and had levels that fell between 0.36 and 5.49 IU/ml. They were allocated into two groups: 100 patients with TSH levels between 0.36--2.49 IU/ml (low-normal TSH ) and 43 patients with TSH levels between 2.5--5.49 IU/ml (high-normal TSH ), and they all had measurements of antiTPO levels. Primary outcomes were rates of antiTPO and demographics comparisons between the two groups. The prevalence of the antiTPO antibody in the high-normal group was 18.6% versus 3% in the low...Continue Reading

Related Concepts

Related Feeds

Autoimmune Thyroiditis

Autoimmune thyroiditis is an inflammatory disease of thyroid gland due to autoimmune responses leading to lymphocytic infiltration of the gland. It is characterized by the presence of circulating thyroid antigen-specific T-cells and thyroid autoantibodies. Discover the latest research on autoimmune thyroiditis here.

Related Papers

The Journal of International Medical Research
S UgurluE Tasan
Annals of the New York Academy of Sciences
Ambika G UnnikrishnanCarani B Sanjeevi
Iranian Journal of Immunology : IJI
Seyed Mohammad GhoraishianMohammad Afkhami-Ardekani
© 2021 Meta ULC. All rights reserved